Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toshiharu Matsushima is active.

Publication


Featured researches published by Toshiharu Matsushima.


Journal of Clinical Microbiology | 2002

Sequence Analysis of the Ribosomal DNA Intergenic Spacer 1 Regions of Trichosporon Species

Takashi Sugita; Masamitsu Nakajima; Reiko Ikeda; Toshiharu Matsushima; Takako Shinoda

ABSTRACT We determined the sequence of the intergenic spacer (IGS) 1 region, which is located between the 26S and 5S rRNA genes, in 25 species of the genus Trichosporon. IGS 1 sequences varied in length from 195 to 719 bp. Comparative sequence analysis suggested that the divergence of IGS 1 sequences has been greater than that of the internal transcribed spacer regions. We also identified five genotypes of T. asahii, which is a major causative agent of deep-seated trichosporonosis, based on the IGS 1 sequences of 43 strains. Most of the isolates that originated in Japan were of genotype 1, whereas the American isolates were of genotype 3 or 5. Our results suggest that analysis of IGS regions provides a powerful method to distinguish between phylogenetically closely related species and that a geographic substructure may exist among T. asahii clinical isolates.


Respirology | 2006

Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis

Akihito Yokoyama; Keiichi Kondo; Masamitsu Nakajima; Toshiharu Matsushima; Toru Takahashi; Masaharu Nishimura; Masashi Bando; Yukihiko Sugiyama; Yoshitaka Totani; Takeshi Ishizaki; Hidenori Ichiyasu; Moritaka Suga; Hironobu Hamada; Nobuoki Kohno

Objective:  Circulating levels of KL‐6, a high MW glycoprotein (MUC1 mucin), are elevated in a majority of patients with a number of interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). However, KL‐6 levels vary from patient to patient. The aim of the present study was to determine whether the serum KL‐6 level at the time of diagnosis predicts prognosis in IPF.


Chest | 2008

Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis

Yoshihiro Kobashi; Keiji Mouri; Shinich Yagi; Yasushi Obase; Naoyuki Miyashita; Niro Okimoto; Toshiharu Matsushima; Takeshi Kageoka; Mikio Oka

OBJECTIVE To evaluate the response to the QuantiFERON-TB-2 Gold (QFT-2G) test (Cellestis Ltd; Carnegie, VIC, Australia) in elderly patients with active tuberculosis (TB) to determine whether the QFT-2G test might be a feasible method for diagnosing TB infection in this group of patients. METHODS The subjects were 30 elderly patients with active TB and 100 younger patients with active TB. The QFT-2G test results were analyzed in relation to combined and separate responses to early secretory antigenic target 6-kD (ESAT-6) protein and culture filtrate protein 10 (CFP-10) antigens. RESULTS Of the 30 elderly patients with active TB, 27% had a positive tuberculin skin test (TST) result and 77% had a positive QFT-2G test result. Of the 100 younger patients with active TB, 70% had a positive TST result and 87% had a positive QFT-2G test result. Although there was no significant difference between the two patient groups in the positive rate for the QFT-2G test results (p = 0.185), there was a significant difference in the rates of positive TST results between the elderly and younger patients (p = 0.012). The positive test result rate for both ESAT-6 and CFP-10 antigens in the elderly patients (17%) was significantly lower than that in younger patients (37%; p = 0.038). There was an indeterminate result for the QFT-2G test in five elderly patients, and this might have been related to the presence of lymphocytopenia due to underlying disease. A negative result on the QFT-2G test was detected in two elderly patients, and this might have been related to the severity of the active TB. CONCLUSION We confirmed that the QFT-2G test might be a more useful method of diagnosing TB infection than the TST for elderly patients if peripheral lymphocyte counts have been preserved.


Annals of Allergy Asthma & Immunology | 1998

Chlamydia pneumoniae and exacerbations of asthma in adults

Naoyuki Miyashita; Yoshifumi Kubota; Masamitsu Nakajima; Yoshihito Niki; Hiroshi Kawane; Toshiharu Matsushima

Background Chlamydia pneumoniae is a frequent causative agent of acute respiratory disease and has been recently reported as a possible case of asthma. Objective We assessed the prevalence of C. pneumoniae infections in adult patients with acute exacerbations of asthma. Methods One hundred sixty-eight adult patients with acute exacerbations of asthma and 108 control subjects matched for age, sex, and smoking status were studied. Nasopharyngeal swab specimens were obtained from all subjects and analyzed by isolation in cell culture and polymerase chain reaction (PCR) test for C. pneumoniae. Serum samples were also obtained and tested for C. pneumoniae-specific antibodies by the microimmunofluorescence test. Results C. pneumoniae was isolated from two (1.2%) asthma patients and none from controls and detected by PCR from nine (5.4%) cases and one (0.9%) control. Both culture positive specimens were also positive in PCR. Further, serologic evidence of acute C. pneumoniae infection was present in 15 (8.9%) of asthma patients and in three (2.8%) of controls (P = .048). The prevalence of C. pneumoniae-specific IgG and IgA was significantly higher in asthma cases than in controls (IgG >/= 1:16; 85.1% versus 67.6%, P = .001; IgA ≥ 1:16: 47.6% versus 16.7%, P < .001). Mean titer of IgG and IgA was also significantly greater in asthma cases than in controls (IgG: 38.8 versus 18.1, P = .0001; IgA: 17.2 versus 6.1, P = .0001). Conclusion Our data suggest that C. pneumoniae infection may trigger acute exacerbations of adult asthma.


Respiration | 2007

The Microbiological and Clinical Effects of Combined Therapy according to Guidelines on the Treatment of Pulmonary Mycobacterium avium Complex Disease in Japan – Including a Follow-Up Study

Yoshihiro Kobashi; Toshiharu Matsushima

Background: The difficulty of treatment for pulmonary Mycobacterium avium complex (MAC) in Japan. Objectives: To investigate the clinical and microbiological effects of treatment according to the guidelines proposed by the American Thoracic Society and the Japanese Society for Tuberculosis and prospective follow-up studies after the completion of treatment of patients with pulmonary MAC disease. Methods: Analysis of the microbiological effects with regard to sputum conversion rate and the sputum relapsing rate and the clinical effects with regard to clinical symptoms and radiological findings for patients with pulmonary MAC disease treated with a regimen consisting of rifampicin, ethambutol, streptomycin, and clarithromycin over 24 months and follow-up over 12 months. Results: Sixty-five patients with pulmonary MAC disease were enrolled in this trial. In 39 patients, negative sputum conversion was observed within 6 months after the initiation of this regimen, 16 relapsed, and 20 experienced clinical worsening within 1 year after the completion of treatment. Although retreatment with the same regimen or a regimen including new quinolones was carried out for these patients, we could not achieve negative sputum conversion and/or clinical improvement. Conclusions: We believe that the dose of clarithromycin for pulmonary MAC disease may be increased and recommend surgery for patients with a localized lesion at early-stage MAC disease to prevent a high rate of relapse.


Respiratory Medicine | 2003

Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex

Jiro Fujita; Yuji Ohtsuki; Eriko Shigeto; Ichizo Suemitsu; Ichiro Yamadori; Shuji Bandoh; Masahiro Shiode; Kazutaka Nishimura; Takeshi Hirayama; Toshiharu Matsushima; Hajime Fukunaga; Toshihiko Ishida

It has been argued whether bronchiectasis is truly caused by MAC infection or just a predisposed condition in which MAC colonizes. Our present study was designed to evaluate the pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex (MAC) lung infection and to demonstrate MAC in the lesion of bronchiectases. A retrospective study was performed in nine cases with positive cultures for MAC in whom lung resections were performed. A determination of whether or not MAC caused pulmonary disease was made using the 1997 criteria required by the American Thoracic Society. In addition, MAC were cultured from all nine lung specimens. Pathological findings of bronchiectases were evaluated in these nine patients. Destruction of bronchial cartilage and smooth muscles layer, obstruction of airway by granulomas, and ulceration of bronchial mucosa were frequently observed. Our present study demonstrates that destruction of fundamental bronchial structure due to extensive granuloma formation throughout the airways was likely the main cause of bronchiectases in MAC infection.


Pathology Research and Practice | 2001

Primary pulmonary primitive neuroectodermal tumor (PNET). A case report.

Yoshiki Mikami; Masamitsu Nakajima; Hiroshi Hashimoto; Isao Irei; Toshiharu Matsushima; Satoshi Kawabata; Toshiaki Manabe

We describe a rare case of a primary primitive neuroectodermal tumor (PNET) in the lung of a 17-year-old girl. Grossly, the tumor, located in the right lower lobe, was relatively well-circumscribed and whitish to yellowish in color with scattered hemorrhagic necrosis. Microscopically, the tumor was composed of ovoid to polygonal cells with a high nuclear to cytoplasmic ratio and relatively scant cytoplasm, arranged in solid sheets with intervening fine fibrovascular stroma. Immunohistochemically, the tumor was positive for the MIC2 gene product, whereas AE1/AE3, CAM5.2, and a variety of neuroendocrine markers such as chromogranin A, synaptophysin, and ProGRP, were negative. Three months after the lobectomy, recurrent tumors were noted in the mediastinum and right thoracic wall, and she died despite combined chemotherapy and radiation therapy. In this case cytogenetic analysis showed a hypertriploid karyotype with multiple numerical and structural chromosomal aberrations, but failed to disclose distinct evidence of translocation between chromosome 11 and 22. However, the reverse transcriptase-polymerase chain reaction (RT-PCR) demonstrated EWS/FLI-1 fusion transcripts, confirming the histopathologic diagnosis of PNET. This case indicates that the primary pulmonary PNET is a highly aggressive neoplasm occurring at a young age, and should prompt combined systemic chemotherapy, even though it is organ-confined.


The Journal of the Japanese Association for Infectious Diseases | 1996

Assay of Specific Anti-Chlamydia pneumoniae Antibodies by ELISA Method

Toshio Kishimoto; Yoshifumi Kubota; Toshiharu Matsushima; Hiroshi Izutsu; Akira Matsumoto; Rinzo Soejima; Kei Numazaki; Shunzo Chiba; Tsutomu Yamazaki; Nozomu Sasaki; Mitsuo Kaku; Jingoro Shimada; Eisaku Iwasaki; Minoru Baba; Yoshiaki Koori; Masanori Aihara; Hiroki Chikumi; Satoru Kosaba; Yukiko Nonaka; Kazunobu Ouchi; Tetsuro Yamamoto; Seizaburo Kashiwagi; Tomotaka Kawayama; Kohtaro Ohizumi; Hiroyuki Nagai; Masaru Nasu; Shigeru Kouno; Hironori Tanaka; Yoichi Hirakata; Masao Tateyama

We measured anti-Chlamydia pneumoniae (C. pneumoniae) specific antibody titers by means of a newly-developed enzyme-linked immunosorbent assay (ELISA) method using an anti-C. pneumoniae specific antibody detection reagent. The clinical usefulness of this method was hereby evaluated. The IgG, IgA and IgM titers in 418 serum specimens obtained from patients with respiratory tract infections were measured by this new ELISA method, and the results were compared with the titers determined for the same specimens with the micro immunofluorescence (Micro-IF) method. The results showed good correlation coefficients for IgG, IgA and IgM. The two assay methods showed high agreement rates for positivity and for negativity. Specimens which did not yield the same results with the ELISA method and the Micro-IF method were subjected to analysis by the Western blot method, and the rates of agreement with the ELISA results were high. In addition, the child (0 approximately 15 yrs old; n = 122) and adult (16 approximately 90 yrs old; n = 133) cases were classified on the basis of being antigen-positive or antigen-negative at the initial examination, and their antibody-positive rates were determined. The adults showed no statistically significant differences in the antibody-positive rates for either IgG or IgA antibodies as a function of the pretreatment antigen status. However, the children showed statistically significant (p < 0.001) differences in the antibody-positive rates for both IgG and IgA antibodies as a function of the antigen status in the antigen-positive group compared with the rates in the antigen-negative group. Furthermore, the IgM-positive rates for the children were high in the antigen-positive group compared with the rates in the antigen-negative group, and the difference was statistically significant (p < 0.001). The IgM-positive rates in the adults were also significantly (p < 0.05) different between the antigen-positive group and the antigen-negative group. The Micro-IF method was applied to 34 specimens from antigen-positive patients, and 22 specimens were found to show an IgG titer of > or = 512 or an IgM titer of > or = 16. The diagnoses of these patients were acute respiratory disease in sixteen, pneumonia in four. Application of the ELISA-method to those 22 specimens showed all of them to exhibit IgG absorbance of > or = 0.6 and IgA absorbance of 0.2. The results described above indicate the clinical usefulness of our new ELISA method for the detection of antibodies specific for C. pneumoniae. The significance of this ELISA method for serological diagnosis of C. pneumoniae infections and the criteria for diagnosis of acute infections were also discussed.


Respiration | 2007

Evaluating the Use of a Streptococcus pneumoniae Urinary Antigen Detection Kit for the Management of Community-Acquired Pneumonia in Japan

Yoshihiro Kobashi; Kouichiro Yoshida; Naoyuki Miyashita; Yoshihito Niki; Toshiharu Matsushima

Background: The urinary antigen detection kit for Streptococcus pneumoniae was tested. Objectives: It was our aim to evaluate the usefulness of the immunochromatographic membrane test by doing a large prospective study of community-acquired pneumonia (CAP) in Japan. Methods: We prospectively evaluated the use of the S. pneumoniae urinary antigen detection kit and analyzed the treatment and clinical effect seen in patients with positive test kit results. One hundred and fifty-six patients with CAP admitted to our hospital between October 2001 and September 2003 were evaluated. Results: In 49% of these CAP patients, the causative microorganisms were isolated. S. pneumoniae was suspected to be the causative microorganism in 15%, but positive results of the urinary antigen detection kit indicated S. pneumoniae to be a probable microorganism in 28%, even though antibiotics had previously been administered to half of the patients. The kit was particularly useful for diagnosing patients with poor quality sputum in whom antibiotics treatment nevertheless had to be selected. Antibiotics appropriate for S. pneumoniae (mainly penicillin) were given. The treatment was found to have excellent clinical results in 89% of the CAP patients. Conclusions: The S. pneumoniae urinary antigen detection kit was considered to be useful in selecting treatment since there was a high level of clinical effectiveness when the most suitable antibiotics were immediately administered to positive patients. The use of the S. pneumoniae urinary antigen kit is rapid and simple compared with conventional microbiological procedures.


Respirology | 2006

Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan

Kazunori Oishi; Hiroyuki Yoshimine; Hiroshi Watanabe; Kiwao Watanabe; Susumu Tanimura; Kenji Kawakami; Akitaka Iwagaki; Hideaki Nagai; Hajime Goto; Shoji Kudoh; Takayuki Kuriyama; Yoshinosuke Fukuchi; Toshiharu Matsushima; Kaoru Shimada; Keizo Matsumoto; Tsuyoshi Nagatake

Background:  A high frequency of drug‐resistant pneumococci has been reported in Asian countries. Few data on the drug‐resistance or serotype of pneumococcal strains responsible for community‐acquired pneumonia (CAP), however, are available for the past two decades in Japan.

Collaboration


Dive into the Toshiharu Matsushima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Niro Okimoto

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroki Hara

Kawasaki Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge